PRESS RELEASE
News
-
-
-
-
PRESS RELEASE
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
Jaguar Health Provides Update on Nasdaq Listing Status. Company requests appeal hearing after receiving delisting notification. Working on comprehensive analysis of Phase 3 trial for cancer therapy-related diarrhea prevention -
PRESS RELEASE
Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Animal Health announces agreement with FDA on clinical field study design for Canalevia-CA1, a canine-specific treatment for chemotherapy-induced diarrhea in dogs, towards full approval -
-
PRESS RELEASE
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
Jaguar Health announces Orphan Drug Designation application for crofelemer for symptomatic relief and treatment of moderate-to-severe diarrhea caused by bacterial, viral, and parasitic infections, including cholera. Crofelemer is a novel plant-based prescription drug derived from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest -
PRESS RELEASE
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions
Magdalena Biosciences, Inc. plans to submit an Investigational New Drug application to the FDA in 2024 for a next-generation psychoactive prescription drug candidate targeting mental health indications such as ADHD, depression, and anxiety. The preclinical study in mice suggests psychoactive activity in a plant extract for potential use as a next-generation psychoactive prescription drug. Magdalena focuses on identifying safe and effective plant-based psychoactive drugs to treat mental health disorders -
PRESS RELEASE
Jaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference
Jaguar Health, Inc. (NASDAQ:JAGX) founder Lisa Conte to present at The Microcap Conference on January 31, 2024 in Atlantic City, NJ and participate in a fireside chat and one-on-one meetings at the Lytham Partners 2024 Investor Select Conference on February 1, 2024. For more information visit jaguar.health -
PRESS RELEASE
Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health’s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)
Jaguar Health, Inc. (NASDAQ:JAGX) has announced the publication of a study evaluating the effects of crofelemer in providing symptomatic relief of diarrhea associated with the irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor neratinib (Nerlynx®) in female dogs. The study, conducted by Napo Pharmaceuticals in collaboration with Puma Biotechnology, highlights the growing need for treatment of cancer therapy-related diarrhea (CTD), a common and debilitating side effect of patients undergoing cancer therapy. The findings of this study, along with two other important studies, provide scientific rationale for the use of crofelemer in humans for the prevention and treatment of CTD, addressing the unmet medical need in the age of targeted cancer therapies.
